ICICI Prudential Nifty Pharma Index Fund · Regular · Growth
NAV
₹20.3573
as of 29 Sept 2026
Expense Ratio
1.18%
AUM
₹122 Cr
Lumpsum returns (CAGR)
- 1Y
- +24.74%
- 3Y
- +19.73%
- 5Y
- —
- Since Inception
- +20.62%
SIP returns (XIRR)
- 1Y
- +27.41%
- 3Y
- +16.92%
- 5Y
- —
- Since Inception
- +19.42%
What history actually did — last 3 years (Oct 2023 – Sept 2026)
A ₹5,000 monthly SIP for the last 3 years (Oct 2023 – Sept 2026)
Real NAV backtest
A ₹5,000 monthly SIP would be worth ₹2,19,676 today — ₹1,75,000 invested, 16.1% XIRR.
₹1,75,000
Invested
₹2,19,676
Value today
16.1%
XIRR (p.a.)
A ₹1,00,000 lumpsum, the last 3 years (Oct 2023 – Sept 2026)
Real NAV backtest
₹1,00,000 invested 3 years ago would be ₹1,73,251 today (20.2% CAGR).
Buying the worst day
Real NAV backtest
₹1,00,000 invested on the worst market day of the last 3 years (Oct 2023 – Sept 2026) (3 Jun 2024) would be ₹1,41,379 today (1.41×).
Historical simulation using actual published NAVs for the stated period. Past performance may or may not be sustained in the future. Not investment advice.
Risk Metrics
Trailing 1 year, annualised0.97
Sharpe Ratio
—
Alpha
—
Beta
0.99
Sortino
14.00%
Std Dev
-7.53%
Max Drawdown
Performance Comparison
Sectoral allocation
as of 31 Aug 2026Each sector links to the mutual funds most exposed to it.
Related reading
Thinking about ICICI Prudential Nifty Pharma Index Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Fund Details
Available transactions
What this fund does
ICICI Prudential Nifty Pharma Index Fund · Regular · Growth is a passively managed fund that tracks a specific market index, aiming to replicate its returns with minimal tracking error. Index funds offer low-cost, diversified exposure to the market with full transparency of holdings.
About This Fund
ICICI Prudential Nifty Pharma Index Fund · Regular · Growth is a Index Fund mutual fund offered by ICICI Prudential Mutual Fund. The fund has been operational for over 3 years. It manages assets worth ₹122 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against Nifty Pharma TRI. The current expense ratio is 1.18%.
Who Should Invest?
- •Cost-conscious investors who prefer passive investing with low expense ratios